Panacea Financial V Tallied Technologies Inc

Court Listener

Automated Summary

Key Facts

Panacea Financial sued Tallied Technologies alleging breach of contract, unjust enrichment, violation of the Delaware Uniform Trade Secrets Act (DUTSA), common law misappropriation of confidential information, tortious interference with prospective business relationships, and unfair competition. The dispute arose from Tallied allegedly misusing confidential information Panacea shared under a Mutual Non-Disclosure Agreement (MNDA) regarding the American Dental Association (ADA) credit card program. Panacea shared confidential information including pricing strategy, cost of funding, and ADA preferences with Tallied in February 2024. Tallied allegedly submitted its own proposal to the ADA RFP independently on July 19, 2024, and undercut Panacea's bid by incorporating confidential pricing information. The Court granted Tallied's motion to dismiss in part (unjust enrichment and common law misappropriation claims) and denied it in part (DUTSA claim, breach of contract, unfair competition, and tortious interference claims).

Transaction Type

Mutual Non-Disclosure Agreement (MNDA) between Panacea Financial and Tallied Technologies regarding confidential information about ADA credit card program partnership

Issues

  • The court examined whether DUTSA's preemption provision displaces Panacea's state law claims for unjust enrichment, common law misappropriation, unfair competition, and tortious interference with prospective business relationships. The court determined that DUTSA preempts claims grounded in the same facts as the trade secret claim, finding that unjust enrichment and common law misappropriation are preempted. However, the court held that unfair competition and tortious interference claims survive preemption because Panacea alleged sufficient independent facts showing Tallied's dishonest interference with its prospective business relationship with the ADA, separate from the trade secret misappropriation allegations.
  • The court analyzed whether Panacea stated a claim for breach of contract based on the Mutual Non-Disclosure Agreement (MNDA) between the parties. The court rejected Tallied's arguments that information about the ADA RFP was not subject to the MNDA and that Panacea's allegations were speculative. The court found that Panacea adequately alleged that Tallied used Panacea's confidential pricing information and feedback to undercut Panacea's bid and ultimately win the ADA RFP, constituting a breach of the MNDA's confidentiality obligations.
  • The court addressed whether Panacea has sufficiently alleged a claim for trade secret misappropriation under the Delaware Uniform Trade Secrets Act (DUTSA). The court analyzed whether Panacea demonstrated that (1) trade secrets exist, (2) Tallied acquired them from Panacea, (3) there was an understanding that secrecy would be respected, and (4) Tallied improperly used or disclosed the information. The court found Panacea adequately alleged that confidential information shared under the MNDA—including proprietary pricing models, interchange fee structures, and knowledge of the ADA's preferences and RFP process—constituted trade secrets that Tallied misappropriated to submit a competitive bid.

Holdings

The Court grants Tallied's motion to dismiss in part and denies it in part. The DUTSA trade secret misappropriation claim survives dismissal. Claims for unjust enrichment and common law misappropriation/conversion of confidential information are dismissed with leave to amend. Claims for unfair competition and tortious interference with prospective business relationships survive dismissal. The breach of contract claim survives dismissal.

Remedies

  • The case management conference originally scheduled for October 7, 2025 is continued to December 2, 2025 at 2:00 p.m.
  • The Court denies Tallied's motion to dismiss Panacea's claims for unfair competition and tortious interference with prospective business relationships. These claims are not preempted by DUTSA and are denied at this stage based on sufficient independent facts supporting them.
  • The Court grants Tallied's motion to dismiss Panacea's claims for unjust enrichment and common law misappropriation/conversion of confidential information. These claims are denied with leave to amend, allowing Panacea to file an amended complaint within 21 days to cure the deficiencies identified in this order.
  • Panacea is granted leave to amend its complaint solely to cure the deficiencies identified in this order. The amended complaint must be filed within 21 days from this order.

Legal Principles

To survive a Rule 12(b)(6) motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to state a claim to relief that is plausible on its face. Courts must accept all factual allegations as true and construe pleadings in the light most favorable to the nonmoving party, but are not required to accept as true allegations that are merely conclusory or unreasonable inferences. Under DUTSA, a trade secret must (1) not be generally known or readily ascertainable, (2) derive independent economic value from not being generally known, and (3) be subject to reasonable efforts to maintain secrecy. DUTSA preempts conflicting state law claims for misappropriation of trade secrets when grounded in the same facts as the trade secret claim.

Precedent Name

  • Bell Atl. Corp. v. Twombly
  • Savor, Inc. v. FMR Corp.
  • Applied Biological Lab'ys, Inc. v. Diomics Corp.
  • Eastman Chem. Co. v. AlphaPet Inc.
  • Navigation Holdings, LLC v. Molavi
  • Yeiser Rsch. & Dev. LLC v. Teknor Apex Co.
  • You Map, Inc. v. Snap Inc.
  • Ashcroft v. Iqbal
  • Alarm.com Holdings, Inc. v. ABS Cap. Partners, Inc.
  • Xsolla (USA), Inc. v. Aghanim Inc.
  • Accenture Global Servs. GMBH v. Guidewire Software Inc.
  • Battaglia Mgmt., Inc. v. Abramowicz
  • Brightstar Corp. v. PCS Wireless, LLC
  • Mendiondo v. Centinela Hosp. Med. Ctr.
  • Knievel v. ESPN
  • Ethypharm S.A. France v. Bentley Pharms., Inc.

Cited Statute

  • Delaware Uniform Trade Secrets Act Section 2007(a)
  • Delaware Uniform Trade Secrets Act Section 2001(4)
  • United States Code Title 28 Section 1332(a)(1)

Judge Name

Jon S. Tigar

Passage Text

  • Accordingly, the Court grants Tallied's motion to dismiss Panacea's claims for unjust enrichment and common law misappropriation/conversion of confidential information, and it denies the motion to dismiss the claims for unfair competition and tortious interference with prospective business relationships.
  • Panacea has thus alleged the nature of the information Tallied misappropriated and how it did so (incorporating Panacea's feedback on revenue share and information about the ADA's preferences into its bid proposal), as well as why circumstances show it was likely that Tallied misappropriated this information—i.e., Tallied's nondisclosure of its own bid submission and its sudden ability to offer the more competitive revenue share after gaining this exact expertise from Panacea's confidential feedback.
  • To state a claim for trade secret misappropriation under the DUTSA, a plaintiff must show that (1) a trade secret exists; (2) the trade secret was acquired by the defendant from the plaintiff; (3) the acquisition was pursuant to an express or implied understanding that the secrecy of the matter would be respected; and (4) the defendant has improperly used or disclosed the secret information to the injury of the plaintiff.